A61K 39/0015
Combination vaccines based on measles-mumps-rubella
Official title: {Combination vaccines based on measles-mumps-rubella}
A61K39/0015 (Combination vaccines based on measles-mumps-rubella) appears on 25 US grants and 27 published applications in this corpus.
Search patents in A61K- Granted patents
- 25
- Published applications
- 27
- Assignees
- 20
- Inventors
- 57
- Latest grant
- 28 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1991 | 3 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 3 | 0 |
| 2001 | 3 | 0 |
| 2002 | 0 | 1 |
| 2003 | 1 | 1 |
| 2004 | 0 | 2 |
| 2005 | 1 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 1 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 1 |
| 2012 | 0 | 1 |
| 2013 | 0 | 1 |
| 2014 | 1 | 3 |
| 2015 | 1 | 3 |
| 2016 | 1 | 0 |
| 2017 | 0 | 1 |
| 2018 | 1 | 4 |
| 2019 | 0 | 0 |
| 2020 | 2 | 3 |
| 2021 | 1 | 1 |
| 2022 | 3 | 0 |
| 2023 | 0 | 2 |
| 2024 | 0 | 1 |
| 2025 | 1 | 0 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Modified clostridial neurotoxins as vaccine and conjugate vaccine platforms28 Apr 2026US 12,611,464 B2The Medical College of Wisconsin, Inc.
- Compositions and methods for stabilization of active agents22 Apr 2025US 12,280,101 B2Trustees of Tufts College
- Modified clostridial neurotoxins as vaccines and conjugate vaccine platforms8 Nov 2022US 11,491,239 B2The Medical College of Wisconsin, Inc.
- Measles virus encoding a tumor antigen28 Jun 2022US 11,369,669 B2Ruprecht-Karls-UniversitäT Heidelberg
- Dried composition of saponin in a liposomal formulation with a neutral lipid, a sterol, and a cryoprotectant19 Apr 2022US 11,304,999 B2Glaxosmithkline Biologicals SA
- Modified clostridial neurotoxins as vaccines and conjugate vaccine platforms23 Jul 2026US 2026/0207764 A1The Medical College of Wisconsin, Inc.
- Modified Clostridial Neurotoxins as Vaccine and Conjugate Vaccine Platforms2 May 2024US 2024/0139332 A1The Medical College of Wisconsin, Inc.
- A live attenuated measles virus vectored vaccine for sars-cov-25 Oct 2023US 2023/0310581 A1Ohio State Innovation Foundation
- Measles virus encoding a tumor antigen9 Mar 2023US 2023/0069933 A1Ruprecht-Karls-UniversitäT Heidelberg
- Bioactive vitamin combinations4 Nov 2021US 2021/0338678 A1BioVit, Inc.
Most cited
By later US patents
- Stabilized live vaccine29US 6,039,958 AThe Research Foundation for Microbial Diseases of Osaka University · 2000
- Stabilizers for live vaccines25US 6,231,860 B1Pasteur Merieux Serums & Vaccins · 2001
- Stabilized live vaccine23US 5,948,411 AThe Research Foundation for Microbial Diseases of Osaka University · 1999
- Stabilizers for lyophilized vaccines22US 6,290,967 B1Merck & Co., Inc. · 2001
- Stabilizers containing recombinant human serum albumin for live virus vaccines19US 6,210,683 B1Merck & Co., Inc. · 2001